Johnson & Johnson (NYSE:JNJ) announced on Monday that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY (nipocalimab-aahu).
The application seeks approval for the treatment of adults with warm autoimmune hemolytic anemia (wAIHA), a rare condition where the immune system prematurely destroys healthy red blood cells.
The Priority Review designation significantly accelerates the regulatory process, shortening the review period to approximately six months compared to the standard ten-month timeline.
The FDA reserves this status for therapies that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition.
The submission is supported by results from the pivotal Phase 2/3 ENERGY study.
In the trial, IMAAVY—a high-affinity, fully human, aglycosylated IgG1 monoclonal antibody—met its primary endpoints by achieving a durable hemoglobin response and demonstrating a significant improvement in patient fatigue scores compared to the placebo group.
Nipocalimab is designed to block the neonatal Fc receptor (FcRn), thereby reducing the levels of circulating pathogenic immunoglobulin G (IgG) antibodies that drive the destruction of red blood cells in wAIHA.
Currently, there are no FDA-approved targeted therapies specifically indicated for wAIHA, leaving patients to rely on steroids, immunosuppressants, or splenectomies.
If approved, IMAAVY would represent a first-in-class mechanism for this underserved population.
Johnson & Johnson plans to present the full data set from the ENERGY study at an upcoming medical conference as it continues to work with the FDA toward a potential late-2026 launch.